SCHEMBL1822003

SCHEMBL1822003

O=C(O)CCCOc1ccc(Br)cc1

nearest known ligand 0.68

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
FFAR1 O14842 4/20 0.58
FFAR4 Q5NUL3 4/20 0.58
PPARA Q07869 3/20 0.56
L3MBTL1 Q9Y468 2/20 0.55
MEN1 O00255 2/20 0.51
KMT2A Q03164 2/20 0.51
NPC1 O15118 1/20 0.51
RAB9A P51151 1/20 0.51
PLA2G4B P0C869 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8355954 0.93 PPARA (0.61) FFAR1FFAR4PPARAL3MBTL1RAB9A
SCHEMBL28543148 0.93 PPARA (0.61) FFAR1FFAR4PPARAL3MBTL1RAB9A
SCHEMBL19489958 0.93 PPARA (0.61) FFAR1FFAR4PPARAL3MBTL1RAB9A
SCHEMBL1822418 0.90 L3MBTL1 (0.67) FFAR1FFAR4PPARAL3MBTL1MEN1
SCHEMBL31448501 0.90 PPARA (0.65) FFAR1FFAR4PPARAL3MBTL1PLA2G4B
SCHEMBL4284638 0.90 PPARA (0.58) FFAR1FFAR4PPARA
SCHEMBL12224519 0.85 L3MBTL1 (0.56) FFAR1FFAR4L3MBTL1MEN1KMT2A
SCHEMBL12224513 0.85 L3MBTL1 (0.56) FFAR1FFAR4L3MBTL1MEN1KMT2A
SCHEMBL19959433 0.84 L3MBTL1 (0.51) FFAR1FFAR4PPARAL3MBTL1MEN1
SCHEMBL31448470 0.84 PPARA (0.73) FFAR1PPARAL3MBTL1PLA2G4B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4618975-A2 INHIBITORS OF TYK2 Vyrnwy Therapeutics, Inc. (US) 2025-09-24 EP disclosed
WO-2024107658-A2 INHIBITORS OF TYK2 VYRNWY THERAPEUTICS, INC. (US) 2024-05-23 WO disclosed
WO-2024107658-A2 INHIBITORS OF TYK2 VYRNWY THERAPEUTICS, INC. (US) 2024-05-23 WO disclosed
CN-112624997-A Preparation method and application of 3-amino-2-oxazolidinone derivatives 中国人民解放军军事科学院军事医学研究院 2021-04-09 CN disclosed
WO-2016025932-A1 SUBSTITUTED POLYCYCLIC ANTIBACTERIAL COMPOUNDS PTC THERAPEUTICS, INC. (US) 2016-02-18 WO disclosed
US-8921359-B2 Inhibitors of beta-secretase VITAE PHARMACEUTICALS, INC. (US) 2014-12-30 US disclosed
US-8921359-B2 Inhibitors of beta-secretase VITAE PHARMACEUTICALS, INC. (US) 2014-12-30 US disclosed
US-8921359-B2 Inhibitors of beta-secretase VITAE PHARMACEUTICALS, INC. (US) 2014-12-30 US disclosed
EP-2324032-B1 INHIBITORS OF BETA-SECRETASE VITAE PHARMACEUTICALS INC (US) 2014-10-01 EP disclosed
EP-2324032-B1 INHIBITORS OF BETA-SECRETASE VITAE PHARMACEUTICALS INC (US) 2014-10-01 EP disclosed
US-6268354-B1 Pharmaceutical composition for antagonizing CCR5 comprising anilide derivative TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 2001-07-31 US disclosed
US-6172061-B1 AIDS THERAPY TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 2001-01-09 US disclosed
US-6166006-A Anilide derivative, production and use thereof TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 2000-12-26 US disclosed
EP-1039899-A2 PHARMACEUTICAL COMPOSITION FOR ANTAGONIZING CCR5 COMPRISING ANILIDE DERIVATIVE Takeda Chemical Industries, Ltd. (JP) 2000-10-04 EP disclosed
EP-1040103-A1 ANILIDE DERIVATIVE, PRODUCTION AND USE THEREOF Takeda Chemical Industries, Ltd. (JP) 2000-10-04 EP disclosed
WO-1999032100-A2 PHARMACEUTICAL COMPOSITION FOR ANTAGONIZING CCR5 COMPRISING ANILIDE DERIVATIVE TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1999-07-01 WO disclosed
WO-1999032468-A1 ANILIDE DERIVATIVE, PRODUCTION AND USE THEREOF TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1999-07-01 WO disclosed
US-4179516-A Ethers of 3,4-dihydro-1-benzoxepin-5-one oxime to treat intestinal disorders ALBERT ROLLAND, S.A. (FR) 1979-12-18 US disclosed
US-4086240-A 1-Thiazolyl-5-phenoxy and phenylthioalkanoyloxyimidazolidinones VELSICOL CHEMICAL CORPORATION (US) 1978-04-25 US disclosed
US-4053480-A 1-THIADIAZOLYL-5-PHENOXY- AND PHENYLTHIOALKANOYLOXY IMIDAZOLIDINONES VELSICOL CHEMICAL CORPORATION (US) 1977-10-11 US disclosed